Drug or technology
4 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
SEP 2, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for oxcarbazepine oral suspension labeling; does not report clinical trial outcomes or comparative efficacy data.
JUL 13, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for labeling change to an established generic oxcarbazepine suspension; regulatory action without clinical trial data.
MAY 28, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of oxcarbazepine labeling; this is a regulatory action, not a clinical evidence report, and does not contain trial outcomes or efficacy data.
MAY 15, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for oxcarbazepine labeling update; does not contain clinical trial data or efficacy evidence.